PCM
KURA icon

Pavaki Capital Management’s Kura Oncology KURA Stock Holding History

Pavaki Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Hold
30,000
– – 0.11% 107
2026
Q1 		$244K Hold
30,000
– – 0.1% 114
2025
Q4 		$312K Buy
+30,000
New +$315K 0.12% 89

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Pavaki Capital Management's KURA Position: Q2 2026 in Review

Pavaki Capital Management held its Kura Oncology (KURA) position steady in Q2 2026 at 30,000 shares worth $329K. The position accounts for 0.11% of the portfolio, ranked #107.

Pavaki Capital Management first reported a position in KURA in Q4 2025 and has held it in 3 quarters since. 205 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Pavaki Capital Management held 30,000 shares of Kura Oncology worth $329K as of Q2 2026.
  • Pavaki Capital Management left its Kura Oncology share count unchanged in Q2 2026.
  • Kura Oncology made up 0.11% of Pavaki Capital Management's portfolio in Q2 2026, its #107 holding.
  • Pavaki Capital Management first reported a position in Kura Oncology in Q4 2025 and has held it in 3 quarters since.
  • 205 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.